Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press49610.17650/1994-4098-2016-12-2-70-76GYNECOLOGY. DIAGNOSISГИНЕКОЛОГИЯ. ДИАГНОСТИКАSerous ovarian carcinoma. Cytological and immunocytochemical and molecular genetic diagnosticsСерозный рак яичников. Цитологическая, иммуноцитохимическая и молекулярно-генетическая диагностикаGrigorukO. G.ГригорукО. Г.
Russian Federation
cytolakod@rambler.ruPupkovaE. E.ПупковаЕ. Э.
Russian Federation
BazulinaL. M.БазулинаЛ. М.
Russian Federation
LazarevA. F.ЛазаревА. Ф.
Russian Federation
Altay branch of N.N. Blokhin Russian Cancer Research CenterАлтайский филиал ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава РоссииAltay Regional Oncology DispensaryКГБУЗ «Алтайский краевой онкологический диспансер»Altay Regional Oncology DispensaryКГБУЗ «Алтайский краевой онкологический диспансер»Altay branch of N.N. Blokhin Russian Cancer Research CenterAltay Regional Oncology DispensaryАлтайский филиал ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава РоссииКГБУЗ «Алтайский краевой онкологический диспансер»1109201612270761109201611092016https://ojrs.abvpress.ru/ojrs/article/view/496

The results of diagnostics of 65 patients with serous ovarian carcinoma are given in the article. Analysis of the investigation has allowed to include 13 patients (20 %) in the group 1 (low grade) and 52 (80 %) in the group 2 (high grade). According to the results of the executed work it is determined that the Immunocytochemical technique allows to verify ovarian carcinoma, differentiating it with carcinoma metastases of the other organs, that is very important for following treatment. In case of sufficient tumour cells in cytological specimens, specimens are valuable material for molecular-genetic researches. According to the results of genetic DNA investigations, suitable for the estimation, there was absence mutation of V600E in the BRAF-gene in all cases. The genetic mutation of KRAS-gene with 5 patients from the group1 (low grade) was noticed. Among them the genetic mutation of G12V was detected in 4 cases and mutation of G12D in 1 case. The mutations in the BRCA1-gene weredetected in 4 cases from the 2th group (high grade) three of them were presented by 5382insC mutation and one of them by T300G mutation. The usage of the multivariate analysis evaluating the cell composition of low and high grade carcinomas was allowed to distinguish the most significant features off ovarian carcinoma cells that will be allow to differentiate them by means of light microscopy.

В статье приведены результаты диагностики 65 пациенток с серозным раком яичника (РЯ). Исходя из данных исследования 13 (20,0 %) пациенток определили в 1-ю группу (low grade) и 52 (80,0 %) – во 2-ю (high grade). Установлено, что использование иммуноцитохимических методик дает возможность верифицировать РЯ, дифференцируя его и метастaзы аденокарцином из других органов, что чрезвычайно важно для последующего лечения. При условии достаточного количества клеток опухоли цитологический материал позволяет провести молекулярно-генетические исследования. По результатам генетического исследования материала ДНК во всех наблюдениях отмечено отсутствие мутации V600E в гене BRAF. В гене KRAS обнаружена генетическая поломка у 5 пациенток 1-й группы, из них в 4 случаях была выявлена мутация G12V и в одном – G12D. Мутации в гене BRCA1 обнаружены в 4 образцах во 2-й группе, 3 из которых представлены мутацией 5382insC, один – T300G. Использование многофакторного анализа при оценке клеточного состава опухолей пациенток с карциномами low grade и high grade позволило выделить наиболее информативные клеточные признаки серозного рака яичника, что позволит их дифференцировать при световой микроскопии.

serous ovarian carcinomacytological and immunocytochemical diagnosticsgene mutation of BRCA1/2KRASBRAFсерозный рак яичникацитологическая и иммуноцитохимическая диагностикамутации генов BRCA1 / 2KRASBRAF1. Аксель Е.М. Статистика злокачественных новообразований женской половой сферы. Онкогинекология 2012;(1):18–23. [Аksel’ Е.М. Statistics of malignant tumors of the female genital sphere. Onkoginekologiya = Оncogynecology 2012;(1):18–23. (In Russ.)].Аксель Е.М. Статистика злокачественных новообразований женской половой сферы. Онкогинекология 2012;(1):18–23. [Аksel’ Е.М. Statistics of malignant tumors of the female genital sphere. Onkoginekologiya = Оncogynecology 2012;(1):18–23. (In Russ.)].2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA. Cancer J Clin 2010;60:277–300.Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA. Cancer J Clin 2010;60:277–300.3. Fleming J.S., Beaugie C.R., Haviv I. et al. Incessant ovulation, infl ammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006;247:4–21.Fleming J.S., Beaugie C.R., Haviv I. et al. Incessant ovulation, infl ammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006;247:4–21.4. Жорданиа К.И., Хохлова С.В. Ранний рак яичников. Наш взгляд на проблему. Онкогинекология 2012(1):51–8. [Zhordania K.I., Khokhlovа S.V. Early ovarian cancer. Our view of the problem. Onkoginekologiya = Оncogynecology 2012(1):51–8. (In Russ.)].Жорданиа К.И., Хохлова С.В. Ранний рак яичников. Наш взгляд на проблему. Онкогинекология 2012(1):51–8. [Zhordania K.I., Khokhlovа S.V. Early ovarian cancer. Our view of the problem. Onkoginekologiya = Оncogynecology 2012(1):51–8. (In Russ.)].5. Ожиганова И.Н. Морфология рака яичников в классификации ВОЗ 2013 года. Практическая онкология 2014;15(4):143–52. [Оzhiganovа I.N. Моrphology of the ovarian cancer in the WHO classification 2013. Prakticheskaya onkologiya = Practical Oncology 2014;15(4):143–52. (In Russ.)].Ожиганова И.Н. Морфология рака яичников в классификации ВОЗ 2013 года. Практическая онкология 2014;15(4):143–52. [Оzhiganovа I.N. Моrphology of the ovarian cancer in the WHO classification 2013. Prakticheskaya onkologiya = Practical Oncology 2014;15(4):143–52. (In Russ.)].6. Жорданиа К.И., Паяниди Ю.Г., Калиничева Е.В. Два пути развития серозного рака яичников. Онкогинекология 2014;(3):42–8. [Zhordania K.I., Payanidi Yu.G., Kalinicheva E.V. Two ways of development of the serous ovarian cancer. Onkoginekologiya = Оncogynecology 2014;(3):42–8. (In Russ.)].Жорданиа К.И., Паяниди Ю.Г., Калиничева Е.В. Два пути развития серозного рака яичников. Онкогинекология 2014;(3):42–8. [Zhordania K.I., Payanidi Yu.G., Kalinicheva E.V. Two ways of development of the serous ovarian cancer. Onkoginekologiya = Оncogynecology 2014;(3):42–8. (In Russ.)].7. Нейштадт Э.Л., Ожиганова И.Н. Опухоли яичника. СПб.: Фолиант, 2014. 350 с. [Neyshtadt E.L., Ozhiganova I.N. Ovarian tumors. Saint Petersburg: Foliant, 2014. 350 p. (In Russ.)].Нейштадт Э.Л., Ожиганова И.Н. Опухоли яичника. СПб.: Фолиант, 2014. 350 с. [Neyshtadt E.L., Ozhiganova I.N. Ovarian tumors. Saint Petersburg: Foliant, 2014. 350 p. (In Russ.)].8. Heintz A.P., Odicino F., Maisonneuve P. et al. Carcinoma of the ovary FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):161–92.Heintz A.P., Odicino F., Maisonneuve P. et al. Carcinoma of the ovary FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):161–92.9. Hennessy B.T., Coleman R.L., Markman M. Ovarian cancer. Lancet 2009;374:1371–82.Hennessy B.T., Coleman R.L., Markman M. Ovarian cancer. Lancet 2009;374:1371–82.10. Kurman R.J., Visvanathan K., Roden R. et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008;198:351–6.Kurman R.J., Visvanathan K., Roden R. et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008;198:351–6.11. Rubin S.C., Benjamin I., Behbakht K. et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Eng J Med 1996;335:1413–6.Rubin S.C., Benjamin I., Behbakht K. et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Eng J Med 1996;335:1413–6.12. Демидова И.А. Наследственно обусловленный рак яичников. Современная онкология 2015;17(3):70–5. [Demidova I.A. Inherited ovarian cancer. Sovremennaya onkologiya = Modern Oncology 2015;17(3):70–5. (In Russ.)].Демидова И.А. Наследственно обусловленный рак яичников. Современная онкология 2015;17(3):70–5. [Demidova I.A. Inherited ovarian cancer. Sovremennaya onkologiya = Modern Oncology 2015;17(3):70–5. (In Russ.)].13. Yang D., Khan S., Sun Y. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557–65.Yang D., Khan S., Sun Y. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557–65.14. Kurman R.J., Ellenson L.H., Ronnett B.M. Blaustein’s pathology of the female genital tract. Sixth edition. Springer, 2011. 1252 p.Kurman R.J., Ellenson L.H., Ronnett B.M. Blaustein’s pathology of the female genital tract. Sixth edition. Springer, 2011. 1252 p.15. Kurman R.J., Сarcanqiu M.L., Herrington C.S., Young R.H. WHO Classificaihion of Tumours of Female Reproductive Organs. Fourth Edition. IARS: Lyon, 2014. 307 p.Kurman R.J., Сarcanqiu M.L., Herrington C.S., Young R.H. WHO Classificaihion of Tumours of Female Reproductive Organs. Fourth Edition. IARS: Lyon, 2014. 307 p.16. Kobayashi Y., Terauchi F., Nishi H. et al. A case of advanced ovarian cancer upstaged on the bases of pleural washing cytology. J Obstet Gynaecol Res 2009;35(3):588–92.Kobayashi Y., Terauchi F., Nishi H. et al. A case of advanced ovarian cancer upstaged on the bases of pleural washing cytology. J Obstet Gynaecol Res 2009;35(3):588–92.17. Campos, S.M., Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol 2010;2010:149362. DOI: 10.1155/2010/149362.Campos, S.M., Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol 2010;2010:149362. DOI: 10.1155/2010/149362.18. Khan N., Afroz N., Aquil B. et al. Neoplastic and non-neoplastic ovarian masses. Diagnosis on cytology. J Cytol 2009;(26): 129–33.Khan N., Afroz N., Aquil B. et al. Neoplastic and non-neoplastic ovarian masses. Diagnosis on cytology. J Cytol 2009;(26): 129–33.19. Koss L.G., Melamed M.R. Tumours of the ovary and fallopian tube: In: Koss’ Diagnostic Cytology and its Histopatologic Bases. 5th ed. New York, Lippincott Williams &Wilkins, 2006. Р. 491–508.Koss L.G., Melamed M.R. Tumours of the ovary and fallopian tube: In: Koss’ Diagnostic Cytology and its Histopatologic Bases. 5th ed. New York, Lippincott Williams &Wilkins, 2006. Р. 491–508.20. Mathur S.R. Ovarian cancer: role of cytology. Indian J Med Paediatric Oncol 2007;27(1):5–6.Mathur S.R. Ovarian cancer: role of cytology. Indian J Med Paediatric Oncol 2007;27(1):5–6.